Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer.
<h4>Background</h4>We hypothesize that women undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis from appendiceal cancer will have a survival advantage compared to men.<h4>Methods</h4>The National Cancer D...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0250726 |
| _version_ | 1818983420905127936 |
|---|---|
| author | Noah S Rozich Samara E Lewis Sixia Chen Kenneth E Stewart Michael B Stout William C Dooley Laura E Fischer Katherine T Morris |
| author_facet | Noah S Rozich Samara E Lewis Sixia Chen Kenneth E Stewart Michael B Stout William C Dooley Laura E Fischer Katherine T Morris |
| author_sort | Noah S Rozich |
| collection | DOAJ |
| description | <h4>Background</h4>We hypothesize that women undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis from appendiceal cancer will have a survival advantage compared to men.<h4>Methods</h4>The National Cancer Database (NCDB) public user file (2004-2014) was used to select patients with PC undergoing CRS and HIPEC from appendiceal cancer. Univariate and multivariable analyses were performed.<h4>Results</h4>1,190 patients with PC from appendiceal cancer underwent HIPEC and CRS. OS was significantly longer for women than for men, with mean and median OS being 73.8 months and 98.2 months for women vs 58.7 months and 82.5 months for men, respectively (p = 0.0032). On multivariable analysis, male sex (HR: 1.444, 95% CI: 1.141-1.827, p = 0.0022) and increasing age (HR: 1.017, 95% CI: 1.006-1.027, p = 0.0017) were both found to be independent risk factors for worse OS.<h4>Conclusion</h4>Women undergoing CRS and HIPEC for PC from appendiceal origin live longer than men undergoing the same treatment. Increasing age was also found to be independent risk factors for worse survival. |
| first_indexed | 2024-12-20T18:02:50Z |
| format | Article |
| id | doaj.art-298e0e7bd8374e76924b1491e36d4003 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T18:02:50Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-298e0e7bd8374e76924b1491e36d40032022-12-21T19:30:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01164e025072610.1371/journal.pone.0250726Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer.Noah S RozichSamara E LewisSixia ChenKenneth E StewartMichael B StoutWilliam C DooleyLaura E FischerKatherine T Morris<h4>Background</h4>We hypothesize that women undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis from appendiceal cancer will have a survival advantage compared to men.<h4>Methods</h4>The National Cancer Database (NCDB) public user file (2004-2014) was used to select patients with PC undergoing CRS and HIPEC from appendiceal cancer. Univariate and multivariable analyses were performed.<h4>Results</h4>1,190 patients with PC from appendiceal cancer underwent HIPEC and CRS. OS was significantly longer for women than for men, with mean and median OS being 73.8 months and 98.2 months for women vs 58.7 months and 82.5 months for men, respectively (p = 0.0032). On multivariable analysis, male sex (HR: 1.444, 95% CI: 1.141-1.827, p = 0.0022) and increasing age (HR: 1.017, 95% CI: 1.006-1.027, p = 0.0017) were both found to be independent risk factors for worse OS.<h4>Conclusion</h4>Women undergoing CRS and HIPEC for PC from appendiceal origin live longer than men undergoing the same treatment. Increasing age was also found to be independent risk factors for worse survival.https://doi.org/10.1371/journal.pone.0250726 |
| spellingShingle | Noah S Rozich Samara E Lewis Sixia Chen Kenneth E Stewart Michael B Stout William C Dooley Laura E Fischer Katherine T Morris Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer. PLoS ONE |
| title | Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer. |
| title_full | Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer. |
| title_fullStr | Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer. |
| title_full_unstemmed | Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer. |
| title_short | Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer. |
| title_sort | women survive longer than men undergoing cytoreductive surgery and hipec for appendiceal cancer |
| url | https://doi.org/10.1371/journal.pone.0250726 |
| work_keys_str_mv | AT noahsrozich womensurvivelongerthanmenundergoingcytoreductivesurgeryandhipecforappendicealcancer AT samaraelewis womensurvivelongerthanmenundergoingcytoreductivesurgeryandhipecforappendicealcancer AT sixiachen womensurvivelongerthanmenundergoingcytoreductivesurgeryandhipecforappendicealcancer AT kennethestewart womensurvivelongerthanmenundergoingcytoreductivesurgeryandhipecforappendicealcancer AT michaelbstout womensurvivelongerthanmenundergoingcytoreductivesurgeryandhipecforappendicealcancer AT williamcdooley womensurvivelongerthanmenundergoingcytoreductivesurgeryandhipecforappendicealcancer AT lauraefischer womensurvivelongerthanmenundergoingcytoreductivesurgeryandhipecforappendicealcancer AT katherinetmorris womensurvivelongerthanmenundergoingcytoreductivesurgeryandhipecforappendicealcancer |